GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.
Histologically confirmed HCC, that is unresectable, recurrent, and/or metastatic... [+9]
Pre-existing illness (e.g., symptomatic congestive heart failure) that would lim... [+16]